HistoSonics Expands Hong Kong Histotripsy Training Center to Support Growing Physician Education Across Asia
HistoSonics has announced the opening of its expanded Histotripsy Training Center in Hong Kong, strengthening the city’s role as a regional hub for physician education, clinical collaboration, and healthcare innovation. The expansion is designed to meet growing demand for advanced training in histotripsy, a noninvasive therapeutic technology that uses focused sound energy to mechanically destroy targeted tissue.
The expanded center builds on the success of the original facility, which was established in May 2025 at Gleneagles Hospital Hong Kong. At the time of its launch, the facility became the first dedicated Histotripsy training center in Asia. Since then, it has welcomed physicians and healthcare professionals from across the region, providing opportunities for hands-on education, clinical observation, and experience sharing related to the emerging technology.
With the expansion, HistoSonics and Gleneagles Hospital Hong Kong aim to increase the center’s capacity to support physicians from across Asia. The facility will provide enhanced opportunities for hands-on procedural training, clinical observation, and multidisciplinary educational programs. Through these activities, physicians will be able to develop a deeper understanding of histotripsy treatment and its potential role in modern clinical practice.
The training programs are expected to cover key aspects of developing and implementing histotripsy services within healthcare institutions. Areas of instruction will include patient selection, treatment planning, procedural workflow, clinical decision-making, and strategies for establishing successful histotripsy programs. By combining structured education with clinical experience, the center is intended to help physicians gain the knowledge and confidence needed to integrate the technology into their practices.
Gleneagles Hospital Hong Kong has served as HistoSonics’ regional Center of Excellence for physician education since 2025. The hospital’s role reflects the growing importance of Hong Kong as a center for advanced medical education and the introduction of innovative healthcare technologies across the Asia-Pacific region.
The continued collaboration between HistoSonics and Gleneagles Hospital Hong Kong is expected to extend beyond physician training. The two organizations plan to build on their existing relationship through expanded cooperation in clinical research, physician education, and the future development of healthcare technologies. This broader partnership is intended to support the development of clinical expertise while contributing to the growing body of knowledge surrounding histotripsy.
“Hong Kong has been at the forefront of histotripsy adoption and physician education in Asia. The expansion of this training center reflects both the growing demand for Histotripsy and our commitment to equipping physicians across the region with the education and experience needed to deliver this technology safely and effectively,” said Mike Blue, Chairman and CEO of HistoSonics.
The expansion also highlights the role of teaching hospitals in supporting the adoption of new medical technologies. As healthcare systems continue to explore innovative treatment options, physician education and clinical collaboration remain important components of successful technology implementation. Training centers can provide healthcare professionals with the opportunity to understand new procedures in a structured environment while learning from experienced clinicians.
Dr. Kenneth Tsang, Regional CEO of IHH Healthcare North Asia and CEO of Gleneagles Hospital Hong Kong, emphasized the hospital’s commitment to innovation and education.
“Innovation creates new possibilities for patient care. As a teaching hospital, we are committed to contributing to physician education, clinical research and partnership, helping translate new technologies into safe, effective treatments that benefit patients today and in the future,” he said.
The facility’s expansion is also supported by the clinical experience of physicians at Gleneagles Hospital Hong Kong who have been involved in the development and evaluation of histotripsy in Asia. Prof. Albert Chan, Director of the Liver Cancer Surgery Centre at Gleneagles Hospital Hong Kong, served as the principal investigator for the first clinical trial on liver cancer involving histotripsy in Asia.
His involvement in the clinical development of the technology underscores the importance of combining research, education, and real-world clinical experience. As physicians across the region explore the potential applications of histotripsy, opportunities to share knowledge and clinical experience can help accelerate understanding of how the technology may be used in different healthcare settings.
Prof. Chan has emphasized the value of continued cooperation and experience sharing among physicians as emerging technologies become part of clinical practice. The development of new treatment approaches requires ongoing communication between clinicians, researchers, hospitals, and technology developers. Training centers such as the expanded facility in Hong Kong can help create a platform for this exchange.
Dr. Vince Lau, Director of the Interventional Radiology Centre at Gleneagles Hospital Hong Kong and co-investigator of the clinical trial, also highlighted the importance of providing clinicians with access to comprehensive training and practical experience. As histotripsy continues to develop, physicians need to understand not only the technology itself but also how to apply it effectively within clinical workflows.
The expanded training center is intended to help clinicians develop the skills and confidence necessary to deliver histotripsy procedures and work toward consistent patient outcomes. Through hands-on instruction and clinical observation, physicians can gain greater familiarity with treatment planning, procedural techniques, and patient management.
Histotripsy has attracted growing interest in the medical community because of its noninvasive approach to tissue destruction. Unlike conventional surgical techniques, the technology uses focused ultrasound energy to mechanically disrupt targeted tissue. This approach has created new opportunities for physicians and researchers to investigate potential applications in the treatment of tumors and other diseases.
Liver tumors represent one of the key areas of interest for histotripsy. The technology is being studied as a potential treatment option for patients with liver tumors, with research focused on its safety, clinical effectiveness, and potential role alongside existing treatment approaches. Continued clinical research and physician education will be important as healthcare professionals evaluate the technology and determine how it may fit into treatment pathways.
The opening of the expanded facility comes as interest in advanced medical technologies continues to grow across Asia. Healthcare systems throughout the region are investing in innovative treatments, medical devices, and clinical capabilities designed to improve patient care. However, the successful adoption of new technologies requires more than access to equipment. It also depends on training, institutional support, clinical research, and the development of experienced physician networks.
By expanding its training infrastructure in Hong Kong, HistoSonics is seeking to support these requirements. The center will provide physicians with access to a dedicated environment for learning and clinical observation while strengthening connections between healthcare professionals from different countries and institutions.
The partnership with Gleneagles Hospital Hong Kong also reflects the importance of collaboration between medical technology companies and healthcare providers. Hospitals can contribute clinical expertise, research capabilities, and patient-care experience, while technology developers provide specialized knowledge, equipment, and training resources. Together, these partnerships can support the responsible introduction of emerging technologies into clinical practice.
For HistoSonics, the expanded Hong Kong center represents a long-term investment in the development of histotripsy expertise across Asia. The company’s continued focus on physician education is expected to support the growth of a regional network of clinicians familiar with the technology and its potential applications.
As more physicians gain exposure to histotripsy through training programs and clinical observation, the technology may become increasingly integrated into discussions around the treatment of liver tumors and other diseases. Continued research will also be necessary to further evaluate its clinical applications and determine how it can complement existing treatment strategies.
The expanded Histotripsy Training Center in Hong Kong therefore represents more than an increase in physical training capacity. It serves as a platform for medical education, clinical collaboration, research, and innovation. By bringing physicians together to share experiences and develop practical expertise, HistoSonics and Gleneagles Hospital Hong Kong aim to contribute to the continued advancement of histotripsy in Asia.
The initiative also reinforces Hong Kong’s position as an important center for medical innovation and professional education in the region. With its combination of advanced healthcare institutions, international connectivity, clinical expertise, and research capabilities, the city provides an important base for supporting the adoption of emerging medical technologies.
As histotripsy continues to evolve, physician training and clinical collaboration will remain central to its development. The expanded Hong Kong facility is expected to play an important role in helping healthcare professionals across Asia understand the technology, develop procedural expertise, and explore its potential applications in patient care.
Through its ongoing partnership with Gleneagles Hospital Hong Kong, HistoSonics is continuing to build a regional foundation for education and clinical development. The company’s expanded investment in Hong Kong reflects its broader commitment to supporting healthcare institutions and physicians as histotripsy advances and its potential role in the treatment of liver tumors and other diseases continues to be explored.
Source link: https://www.businesswire.com/
